盐酸替罗非班治疗急性冠脉综合征疗效分析

Clinical Efficacy of Tirofiban Used in Patients with Acute Coronary Syndrome

目的:观察替罗非班治疗急性冠脉综合征的临床效果和安全性。方法:符合急性冠脉综合征入选标准患者196例,随机分为治疗组(n=108)和对照组(n=105),对照组给予阿司匹林、氯比格雷及低分子肝素治疗,治疗组在上述药物基础上给予微量泵持续泵入替罗非班,疗程为(24～96)小时。观察两组主要终点事件(顽固性心绞痛、再发心肌梗死和死亡)及不良反应发生情况。结果:与对照组相比,主要终点事件有下降趋势,严重不良反应少。结论:替罗非班治疗急性冠脉综合征是安全、有效的。

Objective： To investigate the efficacy and safety of tirofiban in treatment of patients with acute coronary syndrome（ACS）. Methods：213 cases of patients with ACS were randomly divided into treatment group（108cases） and control group （105cases）. Both groups were given Aspirin,clopidogrel and low molecular weight hepain. Besides that ,the treatment group were given tirofibian for （24-96） hours .To observe the composite events （refractory ischemia ,new myocardial and the incidence of death ） .Results：The incidence of composite events in 14 days were significantly reduced in The treatment group compared with control group（p〈0.0 l）,The adverse reactions was fewer in treatment group. Conclusion：Tirofiban is safe and effective in the treatment of patients with ACS.